A First-in-Human, Randomized, Dose-Escalation, Double-Blind, Placebo-Controlled Single Ascending Dose Study to Establish Safety, Lack of Immunogenicity, Tolerability, Pharmacokinetic Parameters, Target Engagement and Pharmacodynamic Effects
Phase of Trial: Phase I
Latest Information Update: 19 Apr 2016
At a glance
- Drugs PRS 080 (Primary)
- Indications Anaemia
- Focus Adverse reactions; First in man
- Sponsors Pieris; Pieris Pharmaceuticals
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
- 07 Dec 2015 Results from this trial were presented at the 57th Annual Meeting of the American Society of Hematology (ASH), according to a Pieris Pharmaceuticals media release.
- 05 Nov 2015 According to a Pieris Pharmaceuticals company media release, data from this trial will be presented at the 57th Annual Meeting of the American Society of Hematology.